CA-ALTIUM-LLC
11.6.2020 09:02:08 CEST | Business Wire | Press release
Altium, the global leader in PCB design software, is partnering with IHS Markit Electronic Parts Solutions to solve one of the major challenges in PCB design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005166/en/
When electronic components become obsolete, design and production can suffer lengthy delays. With an average of 15 end-of-life notices issued every day, part obsolescence is a challenge that most engineers routinely face. To address this design challenge, Altium has partnered with IHS Markit, the world’s most accurate component intelligence source, which provides actionable lifecycle status updates as the PCB is being designed. IHS Markit’s BOM analysis provides current lifecycle status for over 660 million electronic components.
“PCB designers urgently need to understand whether the components they specify are going to be available for the full lifecycle of their end products,” says Ted Pawela, Chief Operating Officer of Altium. “IHS Markit and Altium are partnering to make reliable component lifecycle data and recommended substitutes seamlessly available to them as they design rather than after the fact.”
IHS Markit’s Electronic part and supply chain intelligence is integrated with Altium 365, the world’s only cloud platform for printed circuit board design and realization. Altium 365 works harmoniously with Altium Designer, the industry standard for PCB design, to deliver the most connected experience for PCB design and manufacturing.
The Altium 365 Pro subscription plan provides users with component management capabilities including part and supply chain intelligence powered by IHS, allowing engineers to easily find and replace components that are obsolete or facing end of life.
“By using lifecycle information and alternative part options from IHS, Altium Designer and Altium 365 users can ensure successful supply chain continuity at any point in the PCB design cycle, long before potential end-of-life issues arise,” explains IHS Markit Vice President Bob Braasch.
Altium 365 Pro subscribers can now access IHS Markit technology from within the Altium Designer’s Manufacturer Part Search panel for effortless access to the latest component life cycles, alternative part options and actionable information. With Altium Designer’s ActiveBOM editor, users can harness the latest alternative part choices from IHS Markit, ensuring part availability for the entire Bill of Materials (BOM).
To learn more about the IHS Markit integration, watch the short introductory video: https://www.youtube.com/watch?v=nZmBD9VXhTA .
ABOUT ALTIUM
Altium LLC (ASX: ALU ), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity.
Products include Altium Designer® , Altium Concord Pro™, Altium 365® , Altium NEXUS® , CircuitMaker® , CircuitStudio® , Octopart® , and TASKING® . To learn more about Altium, visit www.altium.com .
ABOUT IHS MARKIT
IHS Markit (NYSE: INFO) is a world leader in critical information, analytics and expertise to forge solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 business and government customers, including 80 percent of the Fortune Global 500 and the world's leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005166/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom